companiesCompany
Shanghai Pharmaceuticals
aka Shanghai Pharmaceuticals Holding, SPH, 上海医药, HKEX:2607, SSE:601607
Shanghai Pharmaceuticals is one of China's largest drug makers and distributors; its research arm is developing SPH4336, an oral CDK4/6 inhibitor for breast cancer.
Overview
Shanghai Pharmaceuticals Holding, listed in Shanghai and Hong Kong, manufactures generic and innovative medicines and runs one of China's biggest pharmaceutical distribution networks. Its oncology research includes SPH4336, a selective CDK4/6 inhibitor in phase 1/2 trials with endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer, and the PD-L1 and TIGIT programmes of its biologics subsidiaries.
Headquarters
Shanghai, CN
Scorecard
All companies#346of 1181 companies, score 10
- phase 3 +3
- modalities +2
- registry trials +5
0 approved, 1 in phase 3, 0 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Type
pharma · HKEX:2607
Stage
Public
Website